Erik S. Lesser/Getty Images News Merck ( NYSE: MRK ) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to jointly develop and commercialize an experimental heart disease therapy. The exclusive partnership centers on HRS-5346, an oral inhibitor of lipoprotein(a), or Lp(a), a key.
